DEFENCE THERAPEUTICS PREPARES FOR
PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST
Canada, October 6th,
2021 -- InvestorsHub NewsWire -- Defence Therapeutics Inc.
or the "Company") CSE:DTC, USOTC:DTCFF, a biotechnology company working
on cancer therapeutics and infectious disease vaccines is
finalizing all required steps in preparation to a pre-IND meeting
to initiate a phase I trial against melanoma using its DC cancer
vaccine candidate AccuVAC-D002.
Defence has successfully exploited the use of its
technology platform to develop a large pipeline of products in
immune-oncology and infectious diseases. Amongst its lead products
is AccuVAC-D002, a DC-based cancer vaccine engineered to treat
melanoma. The AccumTM
technology platform is very efficient at enhancing intracellular
delivery of proteins of pharmacological interests such as ADCs or
vaccine antigens. Defence's scientific team recently identified a
novel function for the use of "free" AccumTM
and its recently developed variants as anti-cancer
"We have successfully moved our product pipeline forward and
developed various cancer vaccines including AccuVAC-D002. With the
synopsis in hand, we are actively working with a large established
CRO in the USA to identify and set-up the site for our Phase I
against melanoma in the first half of 2022", says Mr. Plouffe, CEO
of Defence Therapeutics.
Defence Therapeutics has antibody-drug conjugates and vaccines in
late-stage pre-clinical development and/or undergoing GLP studies.
With two DC cancer vaccines (AccuVAC-D001 and D002) undergoing
manufacturing in clean rooms, Defence is most likely to initiate
its Phase I trials in Q1/Q2 of 2022.
Skin Cancer Treatment Market to reach USD 14.55 Billion with a 7.5%
CAGR by 2027, according to a report by Fortune Business
Therapeutics is a publicly-traded biotechnology company working on
engineering the next generation vaccines and ADC products using its
proprietary platform. The
core of Defence Therapeutics platform is the ACCUMTM
which enables precision delivery of vaccine antigens or ADCs in
their intact form to target cells. As a result, increased efficacy
and potency can be reached against catastrophic illness such as
cancer and infectious diseases.
President, CEO and Director
Statement Regarding "Forward-Looking" Information
This release includes
certain statements that may be deemed "forward-looking statements".
All statements in this release, other than statements of historical
facts, that address events or developments that the Company expects
to occur, are forward-looking statements. Forward-looking
statements are statements that are not historical facts and are
generally, but not always, identified by the words "expects",
"plans", "anticipates", "believes", "intends", "estimates",
"projects", "potential" and similar expressions, or that events or
conditions "will", "would", "may", "could" or "should" occur.
Although the Company believes the expectations expressed in such
forward-looking statements are based on reasonable assumptions,
such statements are not guarantees of future performance and actual
results may differ materially from those in the forward-looking
statements. Factors that could cause the actual results to differ
materially from those in forward-looking statements include
regulatory actions, market prices, and continued availability of
capital and financing, and general economic, market or business
conditions. Investors are cautioned that any such statements are
not guarantees of future performance and actual results or
developments may differ materially from those projected in the
forward-looking statements. Forward-looking statements are based on
the beliefs, estimates and opinions of the Company's management on
the date the statements are made. Except as required by applicable
securities laws, the Company undertakes no obligation to update
these forward-looking statements in the event that management's
beliefs, estimates or opinions, or other factors, should
CSE nor its market regulator, as that term is defined in the
policies of the CSE, accepts responsibility for the adequacy or
accuracy of this release.